Table 1 Relationship of RNU12 expression with clinicopathologic features.
From: RNU12 inhibits gastric cancer progression via sponging miR-575 and targeting BLID
Clinicopathologic feature | Case | Expression levels(lgRQ) | P-value |
|---|---|---|---|
Tumor size (cm) | Â | Â | 0.646 |
 < 5 cm | 56 | 0.018 ± 0.408 |  |
 ≥ 5 cm | 57 | − 0.019 ± 0.449 |  |
Invasion depth | Â | Â | 0.193 |
 < T2 | 10 | 0.168 ± 0.334 |  |
 ≥ T2 | 103 | − 0.017 ± 0.434 |  |
Lauren typing | Â | Â | 0.544 |
 Intestinal type | 77 | − 0.176 ± 0.445 |  |
 Diffuse type | 36 | 0.035 ± 0.391 |  |
TNM stage | Â | Â | 0.070 |
 I + II | 39 | 0.099 ± 0.435 |  |
 III + IV | 74 | − 0.053 ± 0.417 |  |
Lymph node metastasis | Â | Â | 0.011* |
 Non-metastasis | 30 | 0.167 ± 0.439 |  |
 Metastasis | 83 | − 0.061 ± 0.409 |  |
